

2024 Annual Report and Industry Insights

Drug Testing Index™ and Industry Insights

► A comprehensive analysis of workforce drug use trends



Table of Contents

The Quest Diagnostics Drug Testing Index™ (DTI) reveals insights into patterns of drug use among the American workforce. Published annually since 1988, the Drug Testing Index examines positivity rates for workplace drugs tested by the company on behalf of employers. Quest Diagnostics publishes these findings as a public service for government, employers, policymakers and the general public.

Analysis

Workforce Drug Test Cheating Surged in 2023, Finds Quest Diagnostics Drug Testing Index Analysis of Nearly 10 Million Drug Tests2

Urine Drug Tests

Positivity by Combined US Workforce6
Positivity by Testing Category7
Positivity by Testing Reason8
Positivity by Drug Category10
Non-Negative Rates by Specimen
Validity Test (SVT) Category.....13
Non-Negative Rates by Drug/SVT Category15

Oral Fluid Tests

Positivity by Testing Category18
Positivity by Testing Reason19
Positivity by Drug Category20

Hair Drug Tests

Positivity by Testing Category21
Positivity by Testing Reason22
Positivity by Drug Category23

Positivity Rates

Post-Accident vs Pre-Employment25
2023 State Legalized Use Status – Urine Drug Tests33

Quest examines patterns of industry-specific workplace drug use among the American workforce35

North American Industry Classification System

Methodology36
Industry Descriptions.....37

Industry Insights

Overall Positivity Rates38
Positivity Rates by Drug: Marijuana39
Positivity Rates by Drug: Cocaine40
Positivity Rates by Drug: Opiates.....41
Positivity Rates by Drug: Amphetamines.....42
Positivity Rates by Drug: Amphetamine.....43
Positivity Rates by Drug: Methamphetamine.....44

Workforce Drug Test Cheating Surged in 2023, Finds Quest Diagnostics

Drug Testing Index Analysis of Nearly 10 Million Drug Tests



The percentage of employees in the general U.S. workforce whose drug test showed signs of tampering increased by more than six-fold in 2023 versus the prior year, the highest rate ever in more than 30 years of annual reporting. This finding is part of a new analysis of nearly 9.8 million workforce drug tests released today by Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services. To view the full report, visit www.QuestDiagnostics.com/DTI.

The increase in substituted urine specimens in the general U.S. workforce, a population of over 5.5 million, was 633% (0.015% in 2022 versus 0.11% in 2023). Invalid urine specimens in the general U.S. workforce increased 45.2% (0.31% in 2022 versus 0.45% in 2023). A result of substituted or invalid suggests a specimen has been tampered with in an attempt to conceal drug use.*

The increasing rates of substituted or invalid specimens coincide with historically high rates of both general U.S. workforce drug positivity and post-accident marijuana positivity. Drug positivity in the general U.S. workforce was 5.7% in both 2022 and 2023. In 2023, in the combined U.S. workforce, urine drug positivity for all drugs was 4.6%, the same as in 2021 and 2022. This overall positivity is the

highest level in more than two decades, up more than 30% from an all-time low of 3.5% in 2010-2012, and coincides with a sharp increase of 114.3% in post-accident positivity between 2015 and 2023 in the general U.S. workforce.

“The increased rate of both substituted and invalid specimens indicates that some American workers are going to great lengths to attempt to subvert the drug testing process,” said Suhash Harwani, Ph.D., Senior Director of Science for Workforce Health Solutions at Quest Diagnostics. “Given the growing acceptance and use of some drugs, particularly marijuana, it may be unsurprising that some people feel it necessary to try and cheat a drug test. It is possible that our society’s normalization of drug use is fostering environments in which some employees feel it is acceptable to use such drugs without truly understanding the impact they have on workplace safety.”

Similar trends were also seen in the federally mandated, safety-sensitive U.S. workforce, with substituted specimens increasing 370.6% (0.017% in 2022 versus 0.08% in 2023) and invalid rates increasing 36.7% (0.30% in 2022 versus 0.41% in 2023).

“Organizations must have sound policy and procedures to ensure employee drug testing programs have efficacy. Cheating on drug tests not only undermines workplace safety but also jeopardizes the safety of society as a whole,” said Katie Mueller, a senior program manager at the National Safety Council focusing on cannabis safety. “Companies, regulators and policymakers must prioritize accountability for the well-being of all individuals in our communities; lives depend on it.”

*A substituted drug test result means the specimen is not consistent with normal human urine as evidenced by creatinine and specific gravity values that are outside the physiologically producible ranges of human urine. An invalid drug test result indicates that the specimen submitted for drug testing contains an unidentified adulterant, interfering substance, has abnormal physical characteristics (which could damage laboratory instrumentation), or contains a substance that may be a normal constituent of urine at an abnormal concentration.

Marijuana Continues Upward Climb

Marijuana positivity in the general U.S. workforce increased 4.7% (4.3% in 2022 versus 4.5% in 2023). Over five years, marijuana positivity has increased 45.2%, with 2023 reaching a new peak compared to 2019 (3.1% in 2019 versus 4.5% in 2023).

Marijuana Drug Test Positivity Decreases in Federally Mandated, Safety Sensitive Workforce

In the federally mandated safety-sensitive workforce, marijuana positivity decreased nationally 3.1% year over year (0.98% in 2022 versus 0.95% in 2023).

Marijuana positivity stayed the same (1.1% in both 2022 and 2023) in states in which recreational marijuana is legal and decreased 2.2% (0.90% in 2022 versus 0.88% in 2023) in states in which medical marijuana is legal. In states in which neither recreational nor medical marijuana use is legal, marijuana positivity decreased 6.7% (0.89% in 2022 versus 0.83% in 2023) year over year and stayed the same over five years (0.83% in 2019 versus 0.83% in 2023).

“The federally mandated, safety-sensitive population has a lower rate of drug positivity, likely due to the fact that there is decreased drug use when there is an expectation of being drug tested. This is fundamentally the strength of having a drug testing program. The mere expectation of drug testing may

be a deterrent, dissuading individuals from both drug use and applying for positions where such tests are standard practice,” said Dr. Harwani.

Post-accident Marijuana Positivity Continues to Climb

In 2023, post-accident marijuana positivity of urine drug tests in the general U.S. workforce was 7.5%. The new peak follows a steady increase in post-accident marijuana positivity every year from 2015 to 2023. In that 9-year time frame, post-accident marijuana positivity increased 114.3%.

The Quest data aligns with other reports associating marijuana legalization with workplace harms. **A February 2024 study in the Journal of the American Medical Association (JAMA Health Forum)** found recreational marijuana laws that allow recreational marijuana sales were associated with a 10% increase in workplace injuries among individuals aged 20 to 34 years.

“As the prevalence of marijuana positives in the workforce rises, our concern grows,” said Mueller. “The data show an increasing correlation between marijuana use and adverse workplace effects, prompting a call for heightened vigilance and comprehensive strategies to safeguard workplace safety and productivity.”

“Most employers are highly focused on productivity, which can be achieved by improving workforce health and wellness. A well-executed drug testing program can help an organization to maintain a healthier workforce which, based on our data, could decrease the potential for accidents or other unsafe behaviors,” added Dr. Harwani.

Positivity Increased in Industries Associated with Office Work

Overall drug workforce positivity increased in industries associated with “office work,” such as administrative, managerial, and clerical tasks within office environments. Workforce positivity increased in Real Estate and Lending by 17.0% (4.7% in 2022 versus 5.5% in 2023); Professional,

Our 2024 Quest Diagnostics analysis shows overall workforce drug positivity increased in industries associated with “office work,” such as administrative, managerial, and clerical tasks within office environments.



Scientific and Technical Services by 9.3% (4.3% in 2022 versus 4.7% in 2023); Educational Services by 7.9% (from 3.8% in 2022 to 4.1% in 2023); and Public Administration by 5.0% (4.0% in 2022 to 4.2% in 2023).

Marijuana positivity increased in 13 out of 15 industries led by Finance and Insurance which increased 35.7% (2.8% in 2022 versus 3.8% in 2023); Public Administration which increased 23.5% (1.7% in 2022 versus 2.1% in 2023); and Real Estate Rental and Leasing which increased 22.2% (5.4% in 2022 versus 6.5% in 2023).

“It isn’t clear why we’re seeing an increase in overall and marijuana drug positivity in office workers, but it isn’t a stretch that a combination of unprecedented stress and isolation during the pandemic with work-from-home policies during and post-pandemic may be contributing to greater drug use in employees in traditionally white-collar fields,” said Sam Sphar, Vice President and General Manager,

Workforce Health Solutions, Quest Diagnostics. “The results underscore the growing need for mental health support and drug education programs to ensure employees are safe and productive, whether working at home or in the office.”

Urine Drug Test Positivity Among Other Drug Types

Cocaine positivity in the general U.S. workforce increased 9.1% (0.22% in 2022 versus 0.24% in 2023). Amphetamines positivity remained flat (1.5% in 2022 and 2023) and 6-AM (heroin metabolite) positivity decreased 16.7% (0.006% in 2022 versus 0.005% in 2023).

Opiates (codeine/morphine) positivity decreased 12.5% (0.16% in 2022 versus 0.14% in 2023), Opiates (hydrocodone/hydromorphone) decreased 9.4% percent (0.32% in 2022 versus 0.29% in 2023) and Oxycodone (Oxycodone/Oxymorphone) also decreased 3.6% (0.28% in 2022 versus 0.27% in 2023), continuing a downward trend over five years for all three drug categories.

About the Quest Diagnostics Drug Testing Index™

The Quest Diagnostics Drug Testing Index™ (DTI) is a series of reports that provide insights into trends in workforce drug use based on positivity rates of deidentified laboratory tests performed by Quest Diagnostics for a range of illicit, legal and prescription drugs. It examines test results according to three categories of workers: the federally mandated, safety-sensitive workforce; the general U.S. workforce; and the combined U.S. workforce. Federally mandated, safety-sensitive workers include pilots, bus and truck drivers, and workers in nuclear power plants, for whom routine drug testing is mandated by government agencies like the Department of Transportation, the Nuclear Regulatory Commission and the Department of Defense.

The strengths of the DTI analysis include its large, nationally representative sample size, longitudinal monitoring, a testing population that is generally reflective of the U.S. workforce and the quality of the company’s drug testing services to confirm positive results. Limitations include analysis only of employers that perform drug testing with the company, and a lack

of exact cross-specimen comparisons due to variations in substances for which employers test. Quest Diagnostics has analyzed annual workplace drug testing data since 1988 and publishes the findings as a public service. For more information, visit www.QuestDiagnostics.com/DTI.

About Quest Diagnostics Workforce Health Solutions

Through its Workforce Health Solutions, Quest Diagnostics is a leading provider of laboratory testing and other services designed to optimize the health, safety, and wellbeing of employees. Quest Workforce Health Solutions includes population health and biometric and laboratory screening services to identify and act on disease risks in the earliest stages; workforce drug testing services to help identify and pre-empt dangerous workplace drug use; and OSHA-required laboratory screening and vaccination services. Based on the industry leading diagnostics expertise of Quest Diagnostics, our solutions incorporate the latest science, technology and innovations in laboratory medicine and healthcare management to reveal the actions that will improve workforce health, for better medical care and lower costs. For more information, visit WorkforceHealthSolutions.com.

About Quest Diagnostics


Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors, and improve healthcare management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. www.QuestDiagnostics.com

For more information about company policy, employer-based drug testing, visit our **drug screening pages on our website.**



Annual Positivity Rates | *Annual Report*

Urine Drug Tests - For Combined U.S. Workforce



More than 8.4 million tests from January to December 2023


Year	Drug Positivity Rate
1991	8.8%
1992	8.8%
1993	8.4%
1994	7.5%
1995	6.7%
1996	5.8%
1997	5.0%
1998	4.8%
1999	4.6%
2000	4.7%
2001	4.6%

Year	Drug Positivity Rate
2002	4.4%
2003	4.5%
2004	4.4%
2005	4.0%
2006	3.8%
2007	3.8%
2008	3.6%
2009	3.6%
2010	3.5%
2011	3.5%
2012	3.5%

Year	Drug Positivity Rate
2013	3.7%
2014	3.9%
2015	4.0%
2016	4.2%
2017	4.2%
2018	4.4%
2019	4.5%
2020	4.4%
2021	4.6%
2022	4.6%
2023	4.6%

Positivity Rates by Testing Category | *Annual Report*


Urine Drug Tests



Testing Category	2019	2020	2021	2022	2023
Federally Mandated, Safety-Sensitive Workforce	2.4%	2.2%	2.2%	2.4%	2.4%
General U.S. Workforce	5.3%	5.5%	5.6%	5.7%	5.7%
Combined U.S. Workforce	4.5%	4.4%	4.6%	4.6%	4.6%

Positivity Rates by Testing Reason | *Annual Report*

Urine Drug Tests – For Federally Mandated, Safety-Sensitive Workforce




More than 2.8 million tests from January to December 2023

Testing Reason	2019	2020	2021	2022	2023
Follow-Up	5.1%	4.6%	4.3%	4.2%	3.8%
For Cause	13.0%	12.7%	13.8%	12.9%	14.5%
Post-Accident	4.5%	4.3%	4.4%	4.5%	4.6%
Pre-Employment	2.4%	2.1%	2.3%	2.5%	2.5%
Random	2.2%	2.0%	1.9%	1.9%	2.0%
Return to Duty	5.0%	4.5%	4.7%	4.9%	5.2%

Positivity Rates by Testing Reason | *Annual Report*

Urine Drug Tests – For General U.S. Workforce





More than 5.5 million tests from January to December 2023

Testing Reason	2019	2020	2021	2022	2023
Follow-Up	8.3%	7.1%	7.1%	7.3%	8.8%
For Cause	35.7%	34.7%	34.9%	38.6%	39.4%
Post-Accident	9.1%	9.5%	9.7%	10.3%	10.4%
Pre-Employment	4.9%	5.2%	5.4%	5.5%	5.4%
Random	5.6%	5.8%	5.8%	5.9%	6.0%
Return to Duty	6.8%	6.2%	6.3%	7.0%	8.4%

Positivity Rates by Drug Category | *Annual Report*

Urine Drug Tests – For Federally Mandated, Safety-Sensitive Workforce, as a Percentage of All Such Tests





More than 2.8 million tests from January to December 2023

Drug Category	2019	2020	2021	2022	2023
6-AM	0.011%	0.008%	0.005%	0.003%	0.003%
Amphetamines (Amphetamine/Methamphetamine)	0.68%	0.64%	0.69%	0.75%	0.76%
Cocaine	0.25%	0.20%	0.21%	0.21%	0.21%
Marijuana	0.88%	0.79%	0.86%	0.98%	0.95%
MDMA (MDMA/MDA)	0.003%	0.002%	0.002%	0.003%	0.003%
Opiates (Codeine/Morphine)	0.12%	0.10%	0.08%	0.08%	0.07%
Opiates (Hydrocodone/Hydromorphone)	0.35%	0.30%	0.27%	0.24%	0.22%
Oxycodones (Oxycodone/Oxymorphone)	0.26%	0.21%	0.20%	0.18%	0.18%
PCP	0.011%	0.011%	0.010%	0.009%	0.008%

Positivity Rates by Drug Category | *Annual Report*

Urine Drug Tests – For General U.S. Workforce, as a Percentage of All Such Tests




More than 5.5 million tests from January to December 2023

Drug Category	2019	2020	2021	2022	2023
6-AM	0.02%	0.018%	0.013%	0.006%	0.005%
Amphetamines (Amphetamine/ Methamphetamine)	1.3%	1.3%	1.3%	1.5%	1.5%
Barbiturates	0.20%	0.20%	0.18%	0.17%	0.15%
Benzodiazepines	0.43%	0.39%	0.36%	0.35%	0.34%
Cocaine	0.27%	0.22%	0.21%	0.22%	0.24%
Marijuana	3.1%	3.6%	3.9%	4.3%	4.5%
MDMA (MDMA/MDA)	0.008%	0.010%	0.005%	0.004%	0.005%

Drug Category	2019	2020	2021	2022	2023
Methadone	0.16%	0.14%	0.13%	0.12%	0.12%
Opiates	0.25%	0.21%	0.17%	0.16%	0.14%
Opiates (Hydrocodone/ Hydromorphone)	0.37%	0.33%	0.32%	0.32%	0.29%
Oxycodones (Oxycodone/Oxymorphone)	0.34%	0.29%	0.29%	0.28%	0.27%
PCP	0.011%	0.009%	0.008%	0.008%	0.007%
Propoxyphene	0.000%	0.001%	0.000%	0.000%	0.000%

Positivity Rates by Drug Category | *Annual Report*

Urine Drug Tests – For Combined U.S. Workforce, as a Percentage of All Such Tests




More than 8.4 million tests from January to December 2023

Drug Category	2019	2020	2021	2022	2023
6-AM	0.015%	0.011%	0.008%	0.004%	0.004%
Amphetamines (Amphetamine/ Methamphetamine)	1.1%	1.1%	1.1%	1.2%	1.3%
Barbiturates	0.20%	0.20%	0.18%	0.17%	0.15%
Benzodiazepines	0.43%	0.39%	0.36%	0.35%	0.34%
Cocaine	0.26%	0.21%	0.21%	0.22%	0.23%
Marijuana	2.5%	2.7%	2.9%	3.1%	3.1%
MDMA (MDMA/MDA)	0.005%	0.006%	0.004%	0.003%	0.004%
Methadone	0.16%	0.14%	0.13%	0.12%	0.12%

Drug Category	2019	2020	2021	2022	2023
Opiates	0.22%	0.17%	0.15%	0.14%	0.12%
Opiates (Hydrocodone/ Hydromorphone)	0.35%	0.31%	0.28%	0.26%	0.24%
Oxycodones (Oxycodone/Oxymorphone)	0.30%	0.24%	0.24%	0.23%	0.21%
PCP	0.011%	0.010%	0.008%	0.008%	0.007%
Propoxyphene	0.000%	0.001%	0.000%	0.000%	0.000%

Non-Negative Rates by Specimen Validity Test (SVT)^a Category | *Annual Report*

Urine Drug Tests – For Federally Mandated, Safety-Sensitive Workforce, as a Percentage of All Such Tests




More than 2.8 million tests from January to December 2023

SVT Category	2019	2020	2021	2022	2023
Acid-Base	0.010%	0.009%	0.009%	0.008%	0.008%
Invalid	0.21%	0.20%	0.26%	0.30%	0.41%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Substitution	0.017%	0.016%	0.014%	0.017%	0.08%

^a Specimen validity testing is the evaluation of a specimen to determine if it is consistent with a normal human specimen. Tests for specimen validity include tests to determine whether a specimen is adulterated or substituted.

Non-Negative Rates by Specimen Validity Test (SVT)^a Category | *Annual Report*

Urine Drug Tests – For General U.S. Workforce, as a Percentage of All Such Tests




More than 5.5 million tests from January to December 2023

SVT Category	2019	2020	2021	2022	2023
Acid-Base	0.009%	0.009%	0.009%	0.009%	0.008%
Invalid	0.18%	0.17%	0.26%	0.31%	0.45%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Substitution	0.015%	0.012%	0.013%	0.015%	0.11%

^a Specimen validity testing is the evaluation of a specimen to determine if it is consistent with a normal human specimen. Tests for specimen validity include tests to determine whether a specimen is adulterated or substituted.

Non-Negative Rates by Drug/SVT Category | *Annual Report*

Urine Drug Tests – For Federally Mandated, Safety-Sensitive Workforce, as a Percentage of All Non-Negatives




More than 80 thousand non-negative test results from January to December 2023

Drug/SVT Category	2019	2020	2021	2022	2023
6-AM	0.40%	0.31%	0.18%	0.11%	0.11%
Acid-Base	0.34%	0.35%	0.33%	0.29%	0.29%
Amphetamines (Amphetamine/Methamphetamine)	24.3%	25.9%	26.6%	26.8%	26.2%
Cocaine	9.1%	8.1%	8.0%	7.6%	7.2%
Invalid	7.5%	7.9%	10.0%	10.9%	14.1%
Marijuana	31.5%	31.9%	33.1%	35.2%	32.9%
MDMA (MDMA/MDA)	0.09%	0.09%	0.08%	0.09%	0.10%
Opiates (Codeine/Morphine)	4.2%	3.9%	3.1%	3.0%	2.4%
Opiates (Hydrocodone/Hydromorphone)	12.3%	12.0%	10.2%	8.6%	7.6%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Oxycodones (Oxycodone/Oxymorphone)	9.3%	8.5%	7.5%	6.5%	6.0%
PCP	0.41%	0.43%	0.38%	0.33%	0.29%
Substituted	0.61%	0.65%	0.56%	0.60%	2.7%

Non-Negative Rates by Drug/Specimen Validity Test (SVT)^b Category | *Annual Report*

Urine Drug Tests – For General U.S. Workforce, as a Percentage of All Non-Negatives




More than 350,000 non-negative test results from January to December 2023

Drug/SVT Category	2019	2020	2021	2022	2023
6-AM	0.09%	0.08%	0.06%	0.03%	0.03%
Acid-Base	0.16%	0.15%	0.15%	0.14%	0.13%
Amphetamines (Amphetamine/Methamphetamine)	22.7%	21.5%	22.1%	23.6%	23.9%
Barbiturates	2.2%	2.0%	1.9%	1.6%	1.4%
Benzodiazepines	4.6%	3.9%	3.7%	3.4%	3.1%
Cocaine	4.7%	3.7%	3.4%	3.6%	3.7%
Invalid	3.1%	3.0%	4.3%	5.0%	7.0%
Marijuana	53.1%	57.8%	57.5%	56.1%	53.2%
MDMA (MDMA/MDA)	0.05%	0.06%	0.03%	0.03%	0.03%
Methadone	1.7%	1.4%	1.3%	1.1%	1.1%
Opiates	4.5%	3.5%	2.9%	2.6%	2.3%
Opiates (Hydrocodone/Hydromorphone)	0.87%	0.91%	0.85%	0.91%	0.85%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Oxycodones (Oxycodone/Oxymorphone)	1.9%	1.6%	1.6%	1.6%	1.5%
PCP	0.20%	0.16%	0.13%	0.12%	0.11%
Propoxyphene	0.005%	0.007%	0.002%	0.003%	0.002%
Substituted	0.26%	0.21%	0.21%	0.24%	1.7%

^b Specimen validity testing is the evaluation of a specimen to determine if it is consistent with a normal human specimen. Tests for specimen validity include tests to determine whether a specimen is adulterated or substituted.

Non-Negative Rates by Drug/SVT Category | *Annual Report*

Urine Drug Tests – For Combined U.S. Workforce, as a Percentage of All Non-Negatives




More than 430,000 non-negative test results from January to December 2023

Drug/SVT Category	2019	2020	2021	2022	2023
6-AM	0.14%	0.12%	0.08%	0.04%	0.04%
Acid-Base	0.19%	0.18%	0.17%	0.17%	0.16%
Amphetamines (Amphetamine/Methamphetamine)	22.9%	22.2%	22.8%	24.2%	24.3%
Barbiturates	1.8%	1.7%	1.6%	1.3%	1.2%
Benzodiazepines	3.9%	3.3%	3.1%	2.8%	2.5%
Cocaine	5.4%	4.4%	4.1%	4.2%	4.4%
Invalid	3.8%	3.8%	5.2%	6.0%	8.4%
Marijuana	49.7%	53.6%	53.7%	52.6%	49.3%
MDMA (MDMA/MDA)	0.06%	0.07%	0.04%	0.04%	0.04%
Methadone	1.4%	1.1%	1.1%	0.93%	0.89%
Opiates	4.4%	3.6%	2.9%	2.6%	2.3%
Opiates (Hydrocodone/Hydromorphone)	2.7%	2.7%	2.3%	2.2%	2.1%
Oxidizing Adulterants	0.000%	0.000%	0.000%	0.000%	0.000%
Oxycodones (Oxycodone/Oxymorphone)	3.1%	2.7%	2.5%	2.4%	2.4%
PCP	0.23%	0.20%	0.17%	0.16%	0.14%
Propoxyphene	0.004%	0.006%	0.002%	0.003%	0.002%
Substituted	0.31%	0.28%	0.26%	0.30%	1.9%

Positivity Rates by Testing Category | *Annual Report*

Oral Fluid Drug Tests – For General U.S. Workforce




More than 1.3 million tests from January to December 2023

Testing Category	2019	2020	2021	2022	2023
General US Workforce	10.5%	13.6%	7.3%	3.2%	3.3%

Oral fluid decrease (2020-2022) driven by changes in marijuana testing.

Positivity Rates by Testing Reason | *Annual Report*

Oral Fluid Drug Tests – For General U.S. Workforce




More than 1.3 million tests from January to December 2023

Testing Reason	2019	2020	2021	2022	2023
Post-Accident	5.4%	5.8%	8.5%	9.9%	10.9%
Pre-Employment	10.7%	13.9%	7.1%	2.8%	3.0%
Random	6.0%	5.6%	5.5%	4.2%	4.2%

Changes in marijuana testing impacted positivity rates (2020-2022).

Positivity Rates by Drug Category | *Annual Report*

Oral Fluid Drug Tests – For General U.S. Workforce




More than 1.3 million tests from January to December 2023

Drug Category	2019	2020	2021	2022	2023
Amphetamine	0.67%	0.71%	0.80%	0.74%	0.84%
Cocaine/Metabolite	0.57%	0.58%	0.85%	0.83%	1.1%
Marijuana	9.1%	12.3%	14.8%	10.4%	9.9%
Methamphetamine	0.49%	0.53%	0.67%	0.70%	0.66%
Opiates	0.35%	0.31%	0.27%	0.22%	0.17%
Oxycodones	0.28%	0.24%	0.24%	0.23%	0.20%
PCP	0.05%	0.04%	0.05%	0.04%	0.03%

Positivity Rates by Testing Category | *Annual Report*

Hair Drug Tests – For General U.S. Workforce




Nearly 73,000 tests from January to December 2023

Testing Category	2019	2020	2021	2022	2023
General U.S. Workforce	11.2%	12.8%	13.1%	13.1%	15.5%

Hair technology changed in mid-2021 with more drugs tested and some differing cutoffs.

Positivity Rates by Testing Reason | *Annual Report*

Hair Drug Tests – For General U.S. Workforce





Nearly 73,000 tests from January to December 2023

Testing Reason	2019	2020	2021	2022	2023
Pre-Employment	9.0%	9.8%	10.1%	9.9%	12.5%
Random	12.0%	16.7%	18.3%	19.8%	19.1%

Hair technology changed in mid-2021 with more drugs tested and some differing cutoffs.

Positivity Rates by Drug Category | *Annual Report*

Hair Drug Tests – For General U.S. Workforce




Old Technology

Drug Category	2019	2020	2021
Amphetamines (Methamphetamine)	2.4%	2.6%	2.4%
Cocaine	3.2%	3.2%	2.8%
Marijuana	7.1%	8.7%	9.8%
Opiates	0.32%	0.29%	0.20%
PCP	0.012%	0.03%	0.012%

Positivity Rates by Drug Category | *Annual Report*

Hair Drug Tests – For General U.S. Workforce




Nearly 73,000 tests from January to December 2023– New Technology

Drug Category	2021	2022	2023
6-AM	0.08%	0.05%	0.04%
Amphetamine	1.8%	1.7%	1.6%
Benzoyllecgonine	1.1%	1.1%	1.3%
Cocaine	2.7%	2.9%	3.4%
Marijuana	9.5%	10.3%	12.5%
MDA	0.03%	0.02%	0.02%
MDMA	0.13%	0.08%	0.09%

Drug Category	2021	2022	2023
Methamphetamine	2.1%	1.9%	1.8%
Opiates (Codeine/Hydrocodone)	0.37%	0.29%	0.24%
Opiates (Morphine/Hydromorphone)	0.06%	0.04%	0.03%
Oxycodone	0.60%	0.56%	0.45%
Oxymorphone	0.03%	0.05%	0.03%
PCP	0.02%	0.02%	0.02%

Post-Accident vs Pre-Employment Positivity Rates for Marijuana | *Annual Report*

Urine Drug Tests – For Federally Mandated, Safety-Sensitive Workforce, as a Percentage of All Such Tests




More than 2.8 million tests from January to December 2023

Drug Category	2015	2016	2017	2018	2019	2020	2021	2022	2023
Pre-Employment (PE)	0.90%	0.93%	0.99%	1.0%	1.0%	0.95%	1.1%	1.3%	1.2%
Post-Accident (PA)	1.1%	1.2%	1.3%	1.5%	1.6%	1.6%	1.8%	2.1%	2.2%
% Difference PE vs PA	22.2%	29.0%	31.3%	50.0%	60.0%	68.4%	63.6%	61.5%	83.3%

Post-Accident vs Pre-Employment Positivity Rates for Marijuana | *Annual Report*

Urine Drug Tests – For General U.S. Workforce, as a Percentage of All Such Tests




More than 5.5 million tests from January to December 2023

Drug Category	2015	2016	2017	2018	2019	2020	2021	2022	2023
Pre-Employment (PE)	2.3%	2.4%	2.6%	2.8%	3.1%	3.7%	4.1%	4.6%	4.8%
Post-Accident (PA)	3.5%	3.8%	4.2%	4.8%	5.7%	6.4%	6.7%	7.3%	7.5%
% Difference PE vs PA	52.2%	58.3%	61.5%	71.4%	83.9%	73.0%	63.4%	58.7%	56.3%

Post-Accident vs Pre-Employment Positivity Rates for Cocaine | *Annual Report*

Urine Drug Tests – For Federally Mandated, Safety-Sensitive Workforce, as a Percentage of All Such Tests




More than 2.8 million tests from January to December 2023

Drug Category	2019	2020	2021	2022	2023
Pre-Employment (PE)	0.27%	0.21%	0.21%	0.21%	0.21%
Post-Accident (PA)	0.47%	0.44%	0.46%	0.43%	0.46%
% Difference PE vs PA	74.1%	109.5%	119.0%	104.8%	119.0%

Post-Accident vs Pre-Employment Positivity Rates for Cocaine | *Annual Report*

Urine Drug Tests – For General U.S. Workforce, as a Percentage of All Such Tests




More than 5.5 million tests from January to December 2023

Drug Category	2019	2020	2021	2022	2023
Pre-Employment (PE)	0.23%	0.18%	0.18%	0.20%	0.21%
Post-Accident (PA)	0.73%	0.63%	0.66%	0.66%	0.71%
% Difference PE vs PA	217.4%	250.0%	266.7%	230.0%	238.1%

Post-Accident vs Pre-Employment Positivity Rates for Opiates (Hydrocodone/Hydromorphone) | *Annual Report*

Urine Drug Tests – For Federally Mandated, Safety-Sensitive Workforce, as a Percentage of All Such Tests




More than 2.8 million tests from January to December 2023

Drug Category	2019	2020	2021	2022	2023
Pre-Employment (PE)	0.27%	0.22%	0.21%	0.18%	0.17%
Post-Accident (PA)	0.89%	0.81%	0.75%	0.68%	0.60%
% Difference PE vs PA	229.6%	268.2%	257.1%	277.8%	252.9%

Post-Accident vs Pre-Employment Positivity Rates for Opiates (Hydrocodone/Hydromorphone) | *Annual Report*

Urine Drug Tests – For General U.S. Workforce, as a Percentage of All Such Tests




More than 5.5 million tests from January to December 2023

Drug Category	2019	2020	2021	2022	2023
Pre-Employment (PE)	0.26%	0.23%	0.24%	0.24%	0.20%
Post-Accident (PA)	1.1%	0.95%	1.0%	1.0%	0.91%
% Difference PE vs PA	323.1%	313.0%	316.7%	316.7%	355.0%

Post-Accident vs Pre-Employment Positivity Rates for Oxycodones (Oxycodone/Oxymorphone) | *Annual Report*

Urine Drug Tests – For Federally Mandated, Safety-Sensitive Workforce, as a Percentage of All Such Tests




More than 2.8 million tests from January to December 2023

Drug Category	2019	2020	2021	2022	2023
Pre-Employment (PE)	0.22%	0.17%	0.17%	0.16%	0.15%
Post-Accident (PA)	0.58%	0.52%	0.50%	0.44%	0.49%
% Difference PE vs PA	163.6%	205.9%	194.1%	175.0%	226.7%

Post-Accident vs Pre-Employment Positivity Rates for Oxycodones (Oxycodone/Oxymorphone) | *Annual Report*

Urine Drug Tests – For General U.S. Workforce, as a Percentage of All Such Tests




More than 5.5 million tests from January to December 2023

Drug Category	2019	2020	2021	2022	2023
Pre-Employment (PE)	0.28%	0.24%	0.24%	0.24%	0.23%
Post-Accident (PA)	0.77%	0.62%	0.72%	0.69%	0.65%
% Difference PE vs PA	175.0%	158.3%	200.0%	187.5%	182.6%

Marijuana Positivity by 2023 State Legalized Use Status – Urine Drug Tests | *Annual Report*

For Federally Mandated, Safety-Sensitive Workforce, as a Percentage of All Tests for Marijuana Metabolite




More than 2.8 million tests from January to December 2023

Drug Category	2015	2016	2017	2018	2019	2020	2021	2022	2023
Recreational Use	0.75%	0.84%	0.89%	0.95%	0.97%	0.89%	0.96%	1.1%	1.1%
Medical Use Only	0.70%	0.76%	0.82%	0.85%	0.87%	0.77%	0.81%	0.90%	0.88%
Neither Recreational nor Medical Use	0.68%	0.75%	0.82%	0.87%	0.83%	0.72%	0.78%	0.89%	0.83%
National	0.71%	0.78%	0.84%	0.88%	0.88%	0.79%	0.86%	0.98%	0.95%

Marijuana Positivity by 2023 State Legalized Use Status – Urine Drug Tests | *Annual Report*

For General U.S. Workforce, as a Percentage of All Tests for Marijuana Metabolite



More than 5.5 million tests from January to December 2023

Drug Category	2015	2016	2017	2018	2019	2020	2021	2022	2023
Recreational Use	2.4%	2.6%	2.7%	3.2%	3.7%	4.3%	5.0%	5.7%	5.8%
Medical Use Only	2.0%	2.1%	2.1%	2.4%	2.7%	3.1%	3.5%	3.9%	4.0%
Neither Recreational nor Medical Use	2.7%	2.7%	2.8%	2.7%	2.7%	3.0%	3.0%	3.1%	3.3%
National	2.4%	2.5%	2.6%	2.8%	3.1%	3.6%	3.9%	4.3%	4.5%

Drug Testing Index™ Industry Insights


Quest examines patterns of industry-specific workplace drug use among the American workforce

The North American Industry Classification System (NAICS) is the standard used by federal statistical agencies of Canada, Mexico and the U.S. in classifying business establishments for the purpose of collecting, analyzing and publishing statistical data related to the economy. Defining an industry using a production-oriented concept means companies with the same NAICS code share production processes and technologies when producing goods and services. Simply put, an NAICS code identifies a company's primary business activity and allows a comparison of companies in like industries across the continent.

Using a hierarchical structure, an NAICS code is a 6-digit coding system that classifies all economic activity into 20 industry sectors; 5 sectors produce goods and 15 provide some type of service. Each digit in an NAICS code gradually narrows the categories. The first 2 digits of the NAICS code indicate the industry sector—the largest business sector in which a company operates. The third digit is the subsector and the fourth digit is the industry group. The fifth digit designates the NAICS industry and the sixth and final digit designates a company's national industry.

In 1997, the Standard Industrial Classification (SIC) 4-digit system was replaced by NAICS to simplify and modernize the comparison of industries. NAICS undergoes a planned review every 5 years to ensure it remains relevant.

Our data was classified by the industry sector identifier of a company's headquarters location using the most recent system, *2017 NAICS Manual: United States*, detailing 1,057 industries. For more information, visit www.census.gov/eos/www/naics/.



A welder wearing a green jumpsuit, safety glasses, and gloves is working on a metal pipe in a factory setting. Sparks are flying from the welding point. The background shows a large industrial building with a high ceiling and structural beams.

North American Industry Classification System

Methodology

This report of drug use patterns by industry is based on a five-year analysis of American companies that drug test with Quest Diagnostics. Data from more than 15 million urine drug tests include overall positivity rates by industry and by drug category for marijuana, cocaine, opiates, amphetamines and methamphetamine.

- Data includes laboratory-based urine drug tests submitted by the general U.S. workforce for routine testing. Rehabilitation, criminal justice and federally mandated, safety-sensitive testing data are excluded. Positive results are tabulated prior to Medical Review Officer (MRO) evaluation
- Each company is categorized by a single NAICS code. If a company can be categorized by multiple NAICS codes, it is assigned 1 code based on its largest revenue-producing report
- An industry must meet an average annual minimum volume of at least 50,000 urine drug tests to be included in our output. Five NAICS sectors are not included in our data due to insufficient volume. Those sectors are: Agriculture, Forestry, Fishing and Hunting (11); Mining, Quarrying and Oil and Gas Extraction (21); Utilities (22); Management of Companies and Enterprises (55); and Arts, Entertainment and Recreation (71)
- Shifts in customers and testing volume may influence positivity rates over time
- More than 90% of our general U.S. workforce urine testing volume has been categorized. Data are excluded if a company is unable to be reliably classified into a category

Industry Descriptions



11 | Agriculture, Forestry, Fishing and Hunting

Activities of this sector include growing crops, raising animals, harvesting timber and harvesting fish and other animals from farms, ranches or the animals' natural habitats.



21 | Mining, Quarrying and Oil and Gas Extraction

Activities of this sector include extracting naturally occurring mineral solids, such as coal and ore; liquid minerals, such as crude petroleum; gases, such as natural gas; and beneficiating (eg, crushing, screening, washing and flotation) and other preparation at the mine site or as part of mining activity.



22 | Utilities

Activities of this sector include generating, transmitting and/or distributing electricity, gas, steam and water and removing sewage through a permanent infrastructure of lines, mains and pipe.



23 | Construction

Activities of this sector involve erecting buildings and other structures (including additions); heavy construction other than buildings; and alterations, reconstruction, installation and maintenance and repairs.



31-33 | Manufacturing

Activities of this sector involve the mechanical, physical or chemical transformation of materials, substances or components into new products.



42 | Wholesale Trade

Activities of this sector involve selling or arranging for the purchase or sale of goods for resale; capital or durable nonconsumer goods; and raw and intermediate materials and supplies used in production. It also involves providing services incidental to the sale of the merchandise.



44-45 | Retail Trade

Activities of this sector include retailing merchandise generally in small quantities to the general public and providing services incidental to the sale of the merchandise.



48-49 | Transportation and Warehousing

Activities of this sector involve providing transportation of passengers and cargo, warehousing and storing goods, scenic and sightseeing transportation and supporting these activities.



51 | Information

Activities of this sector include distributing information and cultural products, providing the means to transmit or distribute these products as data or communications and processing data.



52 | Finance and Insurance

Activities of this sector involve the creation, liquidation or change in ownership of financial assets (financial transactions) and/or facilitating financial transactions.



53 | Real Estate, Rental and Leasing

Activities of this sector include renting, leasing, or otherwise allowing the use of tangible or intangible assets (except copyrighted works) and providing related services.



54 | Professional, Scientific and Technical Services

Activities of this sector include performing professional, scientific and technical services for the operations of other organizations.



55 | Management of Companies and Enterprises

Activities of this sector involve the holding of securities of companies and enterprises for the purpose of owning controlling interest or influencing their management decisions or administering, overseeing and managing other establishments of the same company or enterprise and normally undertaking the strategic or organizational planning and decision-making role of the company or enterprise.



56 | Administrative Support, Waste Management and Remediation Services

Activities of this sector include performing routine support activities for the day-to-day operations of other organizations.



61 | Educational Services

Activities of this sector include providing instruction and training in a wide variety of subjects.



62 | Health Care and Social Assistance

Activities of this sector include providing health care and social assistance for individuals.



71 | Arts, Entertainment and Recreation

Activities of this sector include operating or providing services to meet varied cultural, entertainment and recreational interests of patrons.



72 | Accommodation and Food Services

Activities of this sector include providing customers with lodging and/or preparing meals, snacks and beverages for immediate consumption.



81 | Other Services (except Public Administration)

Activities of this sector include providing services not elsewhere specified, including repairs, religious activities, grantmaking, advocacy, laundry, personal care, death care and other personal services.




92 | Public Administration

Activities of this sector include administration, management and oversight of public programs by federal, state and local governments.

Source: United States Census Bureau, Office of Management and Budget

Overall Positivity Rates | *Industry Insights*

Urine Drug Tests - General U.S. Workforce




Industry	2019	2020	2021	2022	2023
Accommodation and Food Services ⁷²	5.1%	6.2%	6.5%	7.0%	7.9%
Administrative Support, Waste Management and Remediation Services ⁵⁶	4.7%	5.1%	5.5%	5.5%	5.2%
Construction ²³	4.2%	4.1%	4.6%	4.7%	5.2%
Educational Services ⁶¹	3.2%	3.2%	3.5%	3.8%	4.1%
Finance and Insurance ⁵²	2.8%	3.3%	3.3%	3.6%	3.8%
Health Care and Social Assistance ⁶²	4.5%	4.8%	5.1%	5.3%	5.3%
Information ⁵¹	3.7%	3.8%	4.0%	4.6%	4.6%

Industry	2019	2020	2021	2022	2023
Manufacturing ³¹⁻³³	3.8%	4.0%	4.5%	4.5%	4.4%
Other Services (except Public Administration) ⁸¹	5.5%	5.7%	6.6%	6.2%	6.6%
Professional, Scientific and Technical ⁵⁴	3.3%	3.8%	4.4%	4.3%	4.7%
Public Administration ⁹²	3.3%	3.3%	3.5%	4.0%	4.2%
Real Estate, Rental and Leasing ⁵³	4.8%	5.0%	5.2%	4.7%	5.5%
Retail Trade ⁴⁴⁻⁴⁵	5.5%	6.2%	7.0%	7.7%	7.0%
Transportation and Warehousing ⁴⁸⁻⁴⁹	4.0%	4.4%	5.5%	5.3%	4.8%
Wholesale Trade ⁴²	4.5%	5.2%	5.3%	5.5%	5.3%

Positivity Rates by Drug: Marijuana | *Industry Insights*

Urine Drug Tests - General U.S. Workforce




Industry	2019	2020	2021	2022	2023
Accommodation and Food Services ⁷²	4.8%	6.3%	7.5%	8.1%	9.5%
Administrative Support, Waste Management and Remediation Services ⁵⁶	3.1%	3.6%	4.2%	4.4%	4.5%
Construction ²³	2.2%	2.5%	2.9%	3.0%	3.6%
Educational Services ⁶¹	1.0%	1.0%	1.2%	1.4%	1.6%
Finance and Insurance ⁵²	1.4%	2.1%	2.3%	2.8%	3.8%
Health Care and Social Assistance ⁶²	2.0%	2.4%	2.9%	3.3%	3.7%
Information ⁵¹	2.2%	2.7%	3.0%	3.6%	3.5%

Industry	2019	2020	2021	2022	2023
Manufacturing ³¹⁻³³	2.0%	2.4%	3.1%	3.5%	3.4%
Other Services (except Public Administration) ⁸¹	3.8%	3.7%	5.0%	5.1%	5.7%
Professional, Scientific and Technical ⁵⁴	1.6%	2.2%	2.8%	3.0%	3.4%
Public Administration ⁹²	1.3%	1.3%	1.4%	1.7%	2.1%
Real Estate, Rental and Leasing ⁵³	3.3%	4.0%	5.1%	5.4%	6.6%
Retail Trade ⁴⁴⁻⁴⁵	3.9%	5.0%	6.4%	8.1%	8.2%
Transportation and Warehousing ⁴⁸⁻⁴⁹	2.6%	3.8%	5.4%	6.4%	6.5%
Wholesale Trade ⁴²	2.9%	3.8%	4.5%	5.4%	5.7%

(More than 15 million tests from 2019 - 2023)

Positivity Rates by Drug: Cocaine | *Industry Insights*


Urine Drug Tests - General U.S. Workforce



Industry	2019	2020	2021	2022	2023	Industry	2019	2020	2021	2022	2023
Accommodation and Food Services ⁷²	0.27%	0.23%	0.20%	0.29%	0.27%	Manufacturing ³¹⁻³³	0.17%	0.16%	0.19%	0.20%	0.21%
Administrative Support, Waste Management and Remediation Services ⁵⁶	0.20%	0.17%	0.21%	0.23%	0.21%	Other Services (except Public Administration) ⁸¹	0.23%	0.17%	0.20%	0.24%	0.21%
Construction ²³	0.35%	0.32%	0.30%	0.33%	0.35%	Professional, Scientific and Technical ⁵⁴	0.12%	0.12%	0.11%	0.13%	0.16%
Educational Services ⁶¹	0.04%	0.03%	0.04%	0.04%	0.04%	Public Administration ⁹²	0.14%	0.10%	0.10%	0.09%	0.15%
Finance and Insurance ⁵²	0.06%	0.06%	0.06%	0.06%	0.07%	Real Estate, Rental and Leasing ⁵³	0.26%	0.20%	0.22%	0.29%	0.28%
Health Care and Social Assistance ⁶²	0.14%	0.13%	0.12%	0.13%	0.16%	Retail Trade ⁴⁴⁻⁴⁵	0.20%	0.18%	0.19%	0.22%	0.26%
Information ⁵¹	0.10%	0.11%	0.07%	0.09%	0.09%	Transportation and Warehousing ⁴⁸⁻⁴⁹	0.25%	0.20%	0.24%	0.26%	0.26%
						Wholesale Trade ⁴²	0.25%	0.26%	0.26%	0.28%	0.30%

Positivity Rates by Drug: Opiates | *Industry Insights*

Urine Drug Tests - General U.S. Workforce




Industry	2019	2020	2021	2022	2023
Accommodation and Food Services ⁷²	0.25%	0.27%	0.22%	0.22%	0.17%
Administrative Support, Waste Management and Remediation Services ⁵⁶	0.18%	0.15%	0.14%	0.15%	0.13%
Construction ²³	0.19%	0.17%	0.13%	0.11%	0.10%
Educational Services ⁶¹	0.12%	0.12%	0.12%	0.11%	0.08%
Finance and Insurance ⁵²	0.13%	0.10%	0.10%	0.10%	0.09%
Health Care and Social Assistance ⁶²	0.33%	0.29%	0.23%	0.23%	0.21%
Information ⁵¹	0.12%	0.12%	0.11%	0.10%	0.10%

Industry	2019	2020	2021	2022	2023
Manufacturing ³¹⁻³³	0.21%	0.18%	0.16%	0.12%	0.12%
Other Services (except Public Administration) ⁸¹	0.21%	0.25%	0.18%	0.13%	0.15%
Professional, Scientific and Technical ⁵⁴	0.15%	0.13%	0.13%	0.11%	0.11%
Public Administration ⁹²	0.21%	0.16%	0.14%	0.16%	0.12%
Real Estate, Rental and Leasing ⁵³	0.21%	0.15%	0.15%	0.14%	0.14%
Retail Trade ⁴⁴⁻⁴⁵	0.23%	0.20%	0.24%	0.24%	0.21%
Transportation and Warehousing ⁴⁸⁻⁴⁹	0.14%	0.09%	0.08%	0.08%	0.06%
Wholesale Trade ⁴²	0.16%	0.15%	0.09%	0.08%	0.08%

Positivity Rates by Drug: Amphetamines (Amphetamine and Methamphetamine) | *Industry Insights*

Urine Drug Tests - General U.S. Workforce




Industry	2019	2020	2021	2022	2023
Accommodation and Food Services ⁷²	0.69%	0.83%	0.80%	0.81%	0.81%
Administrative Support, Waste Management and Remediation Services ⁵⁶	0.99%	1.1%	1.1%	1.4%	1.3%
Construction ²³	1.1%	1.1%	1.2%	1.3%	1.3%
Educational Services ⁶¹	1.6%	1.7%	1.9%	2.1%	2.1%
Finance and Insurance ⁵²	1.1%	1.1%	1.1%	1.3%	1.4%
Health Care and Social Assistance ⁶²	1.4%	1.4%	1.5%	1.7%	1.8%
Information ⁵¹	1.1%	1.2%	1.2%	1.5%	1.5%

Industry	2019	2020	2021	2022	2023
Manufacturing ³¹⁻³³	1.2%	1.1%	1.2%	1.3%	1.3%
Other Services (except Public Administration) ⁸¹	1.0%	1.4%	1.3%	1.3%	1.3%
Professional, Scientific and Technical ⁵⁴	1.2%	1.2%	1.3%	1.4%	1.5%
Public Administration ⁹²	1.3%	1.3%	1.5%	1.7%	1.7%
Real Estate, Rental and Leasing ⁵³	0.90%	0.91%	0.97%	1.1%	1.3%
Retail Trade ⁴⁴⁻⁴⁵	1.0%	1.0%	1.2%	1.3%	1.4%
Transportation and Warehousing ⁴⁸⁻⁴⁹	0.71%	0.65%	0.71%	0.80%	0.75%
Wholesale Trade ⁴²	1.0%	0.96%	1.0%	1.2%	1.1%

Positivity Rates by Drug: Amphetamine | *Industry Insights*

Urine Drug Tests - General U.S. Workforce




Industry	2019	2020	2021	2022	2023	Industry	2019	2020	2021	2022	2023
Accommodation and Food Services ⁷²	0.64%	0.80%	0.75%	0.73%	0.74%	Manufacturing ³¹⁻³³	1.1%	1.1%	1.1%	1.2%	1.3%
Administrative Support, Waste Management and Remediation Services ⁵⁶	0.96%	1.0%	1.0%	1.3%	1.3%	Other Services (except Public Administration) ⁸¹	1.0%	1.3%	1.3%	1.3%	1.3%
Construction ²³	1.0%	1.0%	1.1%	1.3%	1.2%	Professional, Scientific and Technical ⁵⁴	1.2%	1.2%	1.2%	1.4%	1.5%
Educational Services ⁶¹	1.6%	1.7%	1.9%	2.1%	2.1%	Public Administration ⁹²	1.3%	1.3%	1.5%	1.7%	1.7%
Finance and Insurance ⁵²	1.1%	1.0%	1.1%	1.3%	1.4%	Real Estate, Rental and Leasing ⁵³	0.86%	0.87%	0.92%	1.1%	1.2%
Health Care and Social Assistance ⁶²	1.4%	1.4%	1.5%	1.6%	1.8%	Retail Trade ⁴⁴⁻⁴⁵	0.99%	1.0%	1.1%	1.3%	1.3%
Information ⁵¹	1.1%	1.2%	1.2%	1.5%	1.5%	Transportation and Warehousing ⁴⁸⁻⁴⁹	0.69%	0.63%	0.68%	0.76%	0.71%
						Wholesale Trade ⁴²	0.97%	0.92%	0.97%	1.1%	1.1%

(More than 15 million tests from 2019 - 2023)

Positivity Rates by Drug: Methamphetamine | *Industry Insights*

Urine Drug Tests - General U.S. Workforce



Industry	2019	2020	2021	2022	2023
Accommodation and Food Services ⁷²	0.18%	0.17%	0.18%	0.21%	0.19%
Administrative Support, Waste Management and Remediation Services ⁵⁶	0.13%	0.12%	0.14%	0.14%	0.13%
Construction ²³	0.24%	0.21%	0.20%	0.21%	0.20%
Educational Services ⁶¹	0.03%	0.03%	0.03%	0.03%	0.02%
Finance and Insurance ⁵²	0.03%	0.04%	0.04%	0.04%	0.05%
Health Care and Social Assistance ⁶²	0.14%	0.10%	0.09%	0.09%	0.11%
Information ⁵¹	0.11%	0.11%	0.08%	0.08%	0.05%

Industry	2019	2020	2021	2022	2023
Manufacturing ³¹⁻³³	0.15%	0.15%	0.17%	0.15%	0.14%
Other Services (except Public Administration) ⁸¹	0.13%	0.12%	0.15%	0.14%	0.13%
Professional, Scientific and Technical ⁵⁴	0.08%	0.09%	0.09%	0.10%	0.11%
Public Administration ⁹²	0.08%	0.07%	0.07%	0.06%	0.09%
Real Estate, Rental and Leasing ⁵³	0.16%	0.15%	0.16%	0.20%	0.19%
Retail Trade ⁴⁴⁻⁴⁵	0.12%	0.13%	0.14%	0.17%	0.15%
Transportation and Warehousing ⁴⁸⁻⁴⁹	0.12%	0.11%	0.12%	0.15%	0.14%
Wholesale Trade ⁴²	0.17%	0.14%	0.16%	0.18%	0.13%



About Quest Diagnostics

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. Quest annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives.

QuestDiagnostics.com/DTI

Image content features models and is intended for illustrative purposes only.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. MI12057 7/2024